Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NANP | Q8TBE9 | 3/20 | 0.38 |
| ▸ | MAG | P20916 | 3/20 | 0.34 |
| ▸ | SIGLEC7 | Q9Y286 | 1/20 | 0.34 |
| ▸ | SELL | P14151 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
| ▸ | NEU3 | Q9UQ49 | 3/20 | 0.33 |
| ▸ | NEU4 | Q8WWR8 | 2/20 | 0.33 |
| ▸ | NEU2 | Q9Y3R4 | 2/20 | 0.33 |
| ▸ | NEU1 | Q99519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20259100 | 0.83 | NANP (0.52) | L3MBTL1NANPMAGSIGLEC7SELL | |
| SCHEMBL31695272 | 0.80 | NANP (0.39) | L3MBTL1NANPMAGSIGLEC7SELL | |
| SCHEMBL29226083 | 0.77 | NANP (0.54) | L3MBTL1NANPMAGSIGLEC7SELL | |
| SCHEMBL31695253 | 0.76 | CD22 (0.51) | NANPMAGSIGLEC7 | |
| SCHEMBL31695064 | 0.76 | NANP (0.38) | NANPMAGSIGLEC7SELLSELP | |
| SCHEMBL17215078 | 0.73 | NEU3 (0.34) | L3MBTL1NANPNEU3NEU4NEU2 | |
| SCHEMBL29226059 | 0.73 | NANP (0.59) | L3MBTL1NANPMAGSIGLEC7SELL | |
| SCHEMBL15491955 | 0.72 | NANP (0.54) | L3MBTL1NANPMAGSIGLEC7SELL | |
| SCHEMBL468825 | 0.72 | NANP (0.54) | L3MBTL1NANPMAGSIGLEC7SELL | |
| SCHEMBL12257455 | 0.72 | NANP (0.53) | L3MBTL1NANPMAGSIGLEC7SELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11639364-B2 | Potent sialyltransferase inhibitors | STICHTING RADBOUD UNIVERSITEIT (NL) | 2023-05-02 | — | — | US | disclosed |
| US-20210107931-A1 | New potent sialyltransferase inhibitors | STICHTING KATHOLIEKE UNIVERSITEIT (NL) | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107931-A1 | New potent sialyltransferase inhibitors | NMT1, NEU1, NMT2 | L3MBTL1 1290/4885NANP 26/4885MAG 160/4885 |
| US-11639364-B2 | Potent sialyltransferase inhibitors | NEU1, NMT1, NEU2 | L3MBTL1 1547/4885NANP 25/4885MAG 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.